AIM logo

AIM IMMUNOTECH INC

AIMNYSE AMERICAN
๐Ÿ† #4993 by market capUS Equity
$0.11โ–ผ $0.01 (โˆ’10.71%)
Market closed ยท at close
๐Ÿ””
Track AIM
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 10.7%
7dโ–ผ 22.3%
14dโ–ผ 27.4%
30dโ–ผ 30.3%
ytdโ–ผ 89.9%
1yโ–ผ 91.3%
๐ŸฆMarket Cap
$4M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-21.5%
Declining
๐Ÿ“ŠGross Margin
-23.2%
Thin
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
48.2x
Expensive
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$0.11 โ€“ $0.12
52-Week Range
$0.11 โ€“ $1.82
Volume (shares)
5,095
Avg Volume (shares)
โ€”
Shares Outstanding
39.9M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
$88,000
Last Q Revenue
$26,000
P/E Ratio
โ€”
P/S Ratio
48.2x
EPS (TTM)
$-3.93
Dividend Yield
โ€”
AIM logo

AIM IMMUNOTECH INC

AIM
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About AIM IMMUNOTECH INC

AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.